Prosthesis–patient mismatch and clinical outcomes: The evidence continues to accumulate  by Dumesnil, Jean G. & Pibarot, Philippe
P
T
J
Editorials Dumesnil and Pibarot
9
ED
ITO
RIA
Lrosthesis–patient mismatch and clinical outcomes:
he evidence continues to accumulateean G. Dumesnil, MD, FRCP (C), FACC, and Philippe Pibarot, DVM, PhD, FACC
I
i
t
o
c
d
l
m
s
t
i
D
G
c
m
c
c
t
t
p
v
b
e
c
g
t
c
w
r
P
T
t
b
p
C
d
c
c
o
w
t
rFrom the Québec Heart Institute, Laval
Hospital, Sainte-Foy, Quebec, Canada.
Received for publication Nov 21, 2005; re-
visions received Dec 13, 2005; accepted for
publication Dec 16, 2005.
Address for reprints: Jean G. Dumesnil,
Québec Heart Institute, Laval Hospital,
2725 Chemin Sainte-Foy, Sainte-Foy, Que-
bec, Canada G1V-4G5 (E-mail: medjgd@
hemes.ulaval.ca).
J Thorac Cardiovasc Surg 2006;131:952-5
0022-5223/$32.00
Copyright © 2006 by The American Asso-
ciation for Thoracic Surgery
See related article on page 1036.t
doi:10.1016/j.jtcvs.2005.12.032
52 The Journal of Thoracic and Cardion this issue of the Journal, Ruel and associates1 report that aortic valve
prosthesis–patient mismatch (PPM) predominantly affects patients with left
ventricular (LV) dysfunction. As they point out, PPM remains a controversial
ssue. On the one hand, there is indeed an increasing body of evidence suggesting
hat PPM occurs frequently and has important clinical consequences.2-13 To the
pposite, some authors have argued that PPM is a rare phenomenon without relevant
linical implications.14-19 The article from Ruel and colleagues1 brings new evi-
ence from two standpoints: (1) It further documents the impact of PPM on
ong-term clinical outcomes such as survival, freedom from heart failure, and LV
ass regression, whereas there has been a paucity of data in this regard and most
tudies have been limited to the short or medium term; (2) it adds a new dimension
o this type of study in that it examines whether PPM and preoperative LV function
nteract with regard to their impact on these outcomes.
efinition of PPM
iven the controversy that has surrounded PPM and to put the findings of Ruel and
oworkers into proper perspective, it is important to review certain essential ele-
ents regarding this concept and its identification. Indeed, the term PPM was first
oined in 1978 by Rahimtoola,20 who defined it as follows: “Mismatch can be
onsidered to be present when the effective prosthetic valve area, after insertion into
he patient, is less than that of a normal human valve.” In his original publication,
he author insisted that the main consequence of PPM would be to produce higher
ostoperative gradients resulting in an increased hemodynamic burden for the
entricle, and he actually provided a graph summarizing his vision of the relation
etween the effective orifice area (EOA) of the prosthesis and postoperative gradi-
nts. However, the graph showed no normalization for body size and, as it stood, it
ould be interpreted as the conceptual relation that would exist between EOA and
radients in a person with average body size. Importantly, it must be emphasized
hat higher postoperative gradients and increased LV workload are inherent to the
oncept of PPM. Hence, an alternate definition for PPM could well be: “PPM occurs
hen the EOA of the prosthesis is too small in relation to the patient’s body size,
esulting in abnormally high postoperative gradients.”
arameter Used to Define PPM
he parameter first proposed to identify PPM has been the indexed EOA, which is
he EOA of the prosthesis divided by the patient’s body surface area.21,22 It should
e emphasized that the EOA is a physiologic parameter derived from hydraulic
rinciples and it corresponds to the area occupied by flow as it exits the valve.
linically, it is calculated from either the continuity equation when using echocar-
iography or the Gorlin formula during cardiac catheterization. Unfortunately, it
annot be predicted from the size of the prosthesis or its geometric area because the
riteria used to calculate the geometric area vary from one type of prosthesis to the
ther; in addition, the ratio between the EOA and the geometric area also varies
idely from one type and/or size of prosthesis to another.8,14,23 The rationale behind
he normalization of the EOA for body surface area is to account for cardiac output
equirements since transvalvular pressure gradients are essentially determined by
he EOA and transvalvular flow, which in turn are largely determined by body size.
vascular Surgery ● May 2006
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LReference values for EOA data exist for each type and
ize of prosthesis,5,8 and they should ideally be derived from
n vivo rather than in vitro values since the latter are often
ore optimistic than the former and are not representative
f the real-life situation. To this effect, it should be empha-
ized that, as was done in this study, the indexed EOA
alculated from such reference values or from postoperative
chocardiograms remains the only parameter that has been
uccessfully validated to predict postoperative outcomes,2-13
s well as to prospectively prevent PPM24 and avoid high
ostoperative gradients.
However, as is the case for many physiologic param-
ters, the EOA has some inherent variability that is
ainly related to the techniques used for its measure-
ent, as well as to a certain flow dependency. For this
eason, some authors have alternatively attempted to
haracterize PPM in terms of the indexed internal geo-
etric area (IGA) rather than the indexed EOA.14-16 In
ontrast to the EOA, the IGA is an anatomic parameter
alculated from the static measurement of the internal
iameter of the prosthesis. In this sense, it is very repro-
ucible and exhibits little variability. However, it has
onsistently been shown to be unrelated to either post-
perative gradients25 or clinical outcomes.14-19 This point
s well illustrated by the recent data of Koch and asso-
iates,19 whereby these authors reported identical values
Abbreviations and Acronyms
EOA  effective orifice area (physiologic parameter
derived from hydraulic principles and
corresponding to the actual area occupied by
flow as it exits the valve; directly related to
hemodynamics and gradients)
GOA geometric orifice area (alternate term used to
describe the IGA)
IGA  internal geometric area (anatomic area of the
prosthesis at inflow, calculated from the static
measurement of the inner diameter of the
prosthesis at that level; no relation to
hemodynamics and gradients)
IOA  indexed orifice area (alternate term used to
identify the IGA indexed for body surface
area; can be misleading since does not specify
whether this is geometric or effective area and
can thus be easily confounded with the EOA
indexed for body surface area, which is an
entirely different parameter)
LV  left ventricular
PPM  prosthesis–patient mismatch (occurs when the
EOA of the prosthesis is too small in relation
to the patient’s body size, resulting in
abnormally high postoperative gradients)or indexed IGA in patients with pericardial valves and t
The Journal of Thoracicatients with allografts whereas peak and mean gradients
ere twice as high in the former as in the latter. Not
urprisingly, the same article found no relation between
he indexed IGA and the clinical outcome of functional
ecovery after surgery. As appropriately pointed out by
he authors, one of the likely explanations for the dis-
repancy between their results and other studies showing
relation between PPM and clinical outcomes is the
ifference in choice of parameters to identify PPM.
Hence, it becomes evident from a practical standpoint
hat, notwithstanding its limitations, the indexed EOA is
he only parameter with proven validity to characterize
PM, prevent its occurrence, and predict postoperative
utcomes. For this reason and to avoid further confusion,
e would thus propose that the term PPM be used only
ith regard to data collected by use of the indexed EOA,
hereas data collected by use of the indexed IGA should
e more appropriately termed prosthesis–patient size.
hese considerations also further emphasize that it is not
he size or the geometric dimensions of a prosthesis that
re clinically relevant, but rather the match between its
nticipated hemodynamic performance and the size of the
atient. When the right parameter is used for its identi-
cation, PPM is also found be to a relatively frequent
henomenon5,8,12 akin to the 40% prevalence (325/805
atients) observed in the present study.
nteraction Between PPM and LV Function
o analyze how the relation between PPM and clinical
utcomes might be affected by LV function is conceptually
ttractive since an increased hemodynamic burden should
heoretically be less well tolerated by a poorly functioning
entricle than by a normal ventricle.26,27 In this sense, the
resent results are extremely valuable in that they indirectly
orroborate the data of Blais and colleagues,8 showing a
trong interaction between PPM and depressed LV function
ith regard to early mortality after AVR, and are the first to
how that such an interaction also exists in relation to late
ortality, heart failure, and LV mass regression.
An important limitation of the study, however, is that
haracterization of LV function was based only on a visual
stimate of the ejection fraction by one or more of four
linded observers. Given that LV function is a major and
ivotal variable of the study, it is indeed unfortunate that the
uthors did not provide some measure of intraobserver or
nterobserver variability and/or did not corroborate their
esults by the use of a more objective method of quantifying
he ejection fraction. In this context, it becomes difficult to
scertain what might have been the margin of error and how
any patients might have been misclassified. This limita-
ion also has to be taken into consideration when analyzing
he clinical implications of the study.
and Cardiovascular Surgery ● Volume 131, Number 5 953
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Lhreshold Values for Identification and
lassification of PPM
he threshold values of indexed EOA used to identify and
lassify PPM have also been a matter of discussion.10 In the
resent study, the authors have elected to dichotomize their
atients between those having an indexed EOA below or
bove 0.85 cm2/m2, whereas other studies have used thresh-
ld values ranging from 0.75 to 0.90 cm2/m2 to dichotomize
atients. An alternate approach has also been to consider
PM as a continuum rather than a dichotomy and, as is
outinely done for native aortic valve disease, to classify
atients according to the degree of severity.7,8,9,12 Indeed,
hen the latter approach is used, a strong relation can be
ound between the degree of severity of PPM and the
revalence of negative outcomes. For unknown reasons, the
resent study tested different thresholds of severity only in
he case of LV mass and did indeed find significant differ-
nces. In the study of Blais and colleagues,8 the impact of
PM was found to increase exponentially in relation to the
egree of severity to the extent that even patients with
ormal LV function were found to have a significant in-
rease in early mortality when faced with severe PPM.
ence, one cannot exclude that a similar result might not
ave been observed in the present study had a similar type
f analysis been performed. The appropriateness of classi-
ying PPM according to the degree of severity is also
orroborated by other studies7,9,12 and is logical in the sense
hat, as for native aortic valve disease, the impact of PPM
hould be viewed in relative terms, that is, in terms of the
egree of imbalance between LV afterload and the status of
V function.27
linical Implications
he clinical implications of this study are important in that
hey clearly demonstrate that PPM has a significant impact
n important clinical outcomes such as late survival, free-
om from heart failure, and LV mass regression and that
his impact is highly modulated by the functional status of
he LV before surgery. The temptation to conclude from
hese findings that PPM is an important consideration only
n patients with reduced LV function and can almost be
ismissed as irrelevant in patients with normal LV function
hould, however, be avoided. Indeed, because PPM was
nalyzed as a dichotomy rather than a continuum, it cannot
e excluded that severe PPM also had an impact in patients
ith normal LV function. Moreover, on examination of
igures 1 and 2 from Ruel’s study,1 it is striking to see that
atients with PPM and normal LV function tended to have
oorer outcomes than those with no PPM and normal LV
unction, as well as those with no PPM and impaired LV
unction. Hence, the impact of PPM on clinical outcomes
ight well be at least as important as that of LV function.
he fact that this did not come out in multivariate analysis
54 The Journal of Thoracic and Cardiovascular Surgery ● Mayight be due to the influence of other confounding vari-
bles. The issue is also further confounded by the potential
ariability in the estimate of the ejection fraction and the
act that patients with borderline values might have been
isclassified. From a practical standpoint, to consider PPM
rrelevant in a patient with normal LV function could be
azardous given that the eventual occurrence of severe PPM
r misclassification of LV function cannot be excluded in
he individual patient.
In this context, it should be emphasized that the projected
ndexed EOA of the prosthesis to be inserted can be calcu-
ated before surgery and that, in the case of an anticipated
PM, alternate procedures such as aortic root enlargement24
r insertion of a better performing valve substitute (eg, supra-
nnular bioprostheses,28 stentless valves,29 newer genera-
ion mechanical valves,30,31 homografts, or the Ross oper-
tion32) can be envisioned.5,8 Castro and coworkers24 have
ndeed demonstrated that such a strategy can be used suc-
essfully to prevent PPM, and most manufacturers now
rovide user-friendly charts allowing easy calculation of the
rojected indexed EOA within the operating room. In any
iven case, this information can easily be incorporated
ithin the clinical decision-making process and used in
iew of the other pertinent clinical factors such as age, level
f physical activity, status of LV function, and concomitant
rocedures. For instance, if one projects moderate PPM in
n elderly patient with reduced physical activity and normal
V function, it might be estimated that the benefits of doing
n alternate procedure to avoid PPM are outweighed by the
nherent risks or disadvantages of doing such a procedure.
n the other hand, the reverse could be true if severe PPM
as projected in the same patient and/or if there was evi-
ence of impaired LV function. In this context, the present
esults are further confirmation that the projected indexed
OA should routinely be calculated before aortic valve
eplacement and become an integral part of the clinical
ecision-making process. Finally, the observation that PPM
as a significant impact on LV mass regression only in
atients with impaired LV function is new and intriguing. It
ill require further validation and documentation with re-
ard to physiopathology and potential clinical implications.
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